Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

This study has been completed.

Study NCT00230178 Information provided by Sanofi-Aventis

First Received on September 28, 2005. Last Updated on January 8, 2010 History of Changes

Results First Received: July 22, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Prevention
Conditions:	Tumor Lysis Syndrome Cancer Hyperuricemia
Interventions:	Drug: Rasburicase (SR29142) Drug: Allopurinol

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Rasburicase	Rasburicase (0.20 mg/kg/day) given as a single agent for 5 days
Rasburicase + Allopurinol	Rasburicase (0.20 mg/kg/day) given alone as a single agent from Day 1 through Day 3, followed by oral allopurinol (300 mg/day) given from Day 3 through Day 5 (Day 3 is an overlap)
Allopurinol	Allopurinol (300 mg/day) given alone as a single agent for 5 days

Participant Flow: Overall Study

	Rasburicase	Rasburicase + Allopurinol	Allopurinol
STARTED	94 ^[1]	93	93
Treated	92 ^[2]	92	91
COMPLETED	90	86	86
NOT COMPLETED	4	7	7
Adverse Event	1	5	2
Withdrawal by Subject	0	0	1
Various other reasons	3	2	4

[1]	Intent-to-treat (ITT)population: randomized patients
[2]	Modified ITT population: ITT patients with at least 1 dose of study drug

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Rasburicase	Rasburicase (0.20 mg/kg/day) given as a single agent for 5 days
Rasburicase + Allopurinol	Rasburicase (0.20 mg/kg/day) given alone as a single agent from Day 1 through Day 3, followed by oral allopurinol (300 mg/day) given from Day 3 through Day 5 (Day 3 is an overlap)
Allopurinol	Allopurinol (300 mg/day) given alone as a single agent for 5 days

Baseline Measures

	Rasburicase	Rasburicase + Allopurinol	Allopurinol	Total
Number of Participants [units: participants]	94	93	93	280
Age, Customized [units: participants]
<65 years	63	65	69	197
>=65 years	31	28	24	83
Gender [units: participants]
Female	35	42	29	106
Male	59	51	64	174

Outcome Measures

Show All Outcome Measures

1. Primary:

Plasma Uric Acid Responder [ Time Frame: Day 3 through Day 7 ]

Show Outcome Measure 1

2. Secondary:

Plasma Uric Acid [ Time Frame: Day 1 to Day 7 ]

Show Outcome Measure 2

3. Secondary:

Time to Uric Acid Control [ Time Frame: Day 1 to Day 7 ]

Show Outcome Measure 3

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: International Clinical Development, Clinical Study Director
Organization: Sanofi-aventis
e-mail: GV-Contact-us@sanofi-aventis.com

No publications provided

Responsible Party:	International Clinical Development, Clinical Study Director, sanofi-aventis
ClinicalTrials.gov Identifier:	NCT00230178 History of Changes
Other Study ID Numbers:	EFC4978
Study First Received:	September 28, 2005
Results First Received:	July 22, 2009
Last Updated:	January 8, 2010
Health Authority:	United States: Food and Drug Administration